Plain-English translation of NCT05268107 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers know that Asian and African American people develop eczema (atopic dermatitis) more often than Caucasian people, but we don't fully understand why. This study will give you , a medication that helps control eczema, and carefully track how your immune system responds to it. By comparing responses across different ethnic groups, scientists hope to understand the root causes of eczema and make better, more personalized treatments.
Most research on eczema has focused on Caucasian patients, leaving a big gap in understanding why other ethnic groups experience this condition differently. This medication appears to work well for some people but not others, and this trial will help researchers figure out if those differences are connected to how different immune systems respond to the treatment.
You likely qualify if…
You likely don't qualify if…
You will receive injections as part of the study. Researchers will take blood and possibly skin samples to examine how your immune system reacts to the medication. You'll have visits at the clinic where doctors will assess your skin and ask about your symptoms. The study involves three ethnic groups (Asian, African American, and Caucasian) all receiving the same treatment, so researchers can directly compare how the medication works across different populations.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States